I'm no big fan of Friedland, but when I first heard of the company as I remember it, one of the highlights on their website was Friedland's association with the company. I don't know that it was stated there, but I did assume that Friedland was being compensated by the company.
Certainly Friedland was promoting it back then, in fact at last year's Wall St. Conference he took over the presentation from Ziv, who was an embarrassment, but what he had to say had more to do with his self interest than promoting the company. At the time, most were thrilled to be associated with him as he was considered to be a major force in the industry.
I'm frankly happy that the company isn't associated with Friedland, but that's largely because I wasn't that impressed with him when I saw the presentations he was making. I believe that we're far better served by the people who're now our leadership than back when Ziv and Friedland were the voice of OWCP.
On the website, the presentation that's referenced is still from November of last year. The site appears to be under development, and may be a step in the right direction, but I believe the corporate presentation needs to be updated, and I'd be thrilled is they supplemented the information on the site to include things like whether the various trials that are upcoming are being done with people with disease, or if all Phase 1 Trials are all being done with healthy people. I believe news of efficacy in people with the diseases being targeted is most important.
I believe if efficacy is clearly seen in Phase 1 or 2 Trials, those products will go on sale in cannabis stores, and the stock will see new all time highs. In the case of the cream, we know it cannot happen until we have data for Phase 2, but I cannot say that about any other case because I don't know if people with diseases that could benefit are being used in the other Phase 1 Trials.
In essentially every oncology trial I've ever seen, the drug being tried was generally used with some of the sickest people, even if that was really not the intended target. I still believe that many great drugs never go beyond Phase 1 because improvement isn't seen in the sickest of people, and they sometimes have side effects where DLT is called at levels far lower than if people who the drug was intended for were tried. We're not dealing with such deadly diseases for the most part, so I believe we'll see improvements from our Phase 1's as dosage is raised to what will be determined to be an effective level. If these Phase 1's are created like most are today, if efficacy is seen, it will be possible to dose a larger number of patients at the level determined effective, so the trial could more honestly be called a Phase 1/2. Of course the key to this is dosing people with disease, if all participants are healthy, you start from scratch with Phase 2.
Gary
Certainly Friedland was promoting it back then, in fact at last year's Wall St. Conference he took over the presentation from Ziv, who was an embarrassment, but what he had to say had more to do with his self interest than promoting the company. At the time, most were thrilled to be associated with him as he was considered to be a major force in the industry.
I'm frankly happy that the company isn't associated with Friedland, but that's largely because I wasn't that impressed with him when I saw the presentations he was making. I believe that we're far better served by the people who're now our leadership than back when Ziv and Friedland were the voice of OWCP.
On the website, the presentation that's referenced is still from November of last year. The site appears to be under development, and may be a step in the right direction, but I believe the corporate presentation needs to be updated, and I'd be thrilled is they supplemented the information on the site to include things like whether the various trials that are upcoming are being done with people with disease, or if all Phase 1 Trials are all being done with healthy people. I believe news of efficacy in people with the diseases being targeted is most important.
I believe if efficacy is clearly seen in Phase 1 or 2 Trials, those products will go on sale in cannabis stores, and the stock will see new all time highs. In the case of the cream, we know it cannot happen until we have data for Phase 2, but I cannot say that about any other case because I don't know if people with diseases that could benefit are being used in the other Phase 1 Trials.
In essentially every oncology trial I've ever seen, the drug being tried was generally used with some of the sickest people, even if that was really not the intended target. I still believe that many great drugs never go beyond Phase 1 because improvement isn't seen in the sickest of people, and they sometimes have side effects where DLT is called at levels far lower than if people who the drug was intended for were tried. We're not dealing with such deadly diseases for the most part, so I believe we'll see improvements from our Phase 1's as dosage is raised to what will be determined to be an effective level. If these Phase 1's are created like most are today, if efficacy is seen, it will be possible to dose a larger number of patients at the level determined effective, so the trial could more honestly be called a Phase 1/2. Of course the key to this is dosing people with disease, if all participants are healthy, you start from scratch with Phase 2.
Gary
1
